TENET HEALTHCARE CORP
DFAN14A, 2000-09-26
GENERAL MEDICAL & SURGICAL HOSPITALS, NEC
Previous: ALLIANCE BALANCED SHARES INC/NJ, NSAR-B, EX-99, 2000-09-26
Next: TENET HEALTHCARE CORP, DFRN14A, 2000-09-26

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934

  Filed by the Registrant  [   ]
  Filed by a Party other than the Registrant  [X]
  Check the appropriate box:
  [   ] Preliminary Proxy Statement                  [    ] Confidential, for Use of the Commission Only (as permitted
                                                                            by Rule 14a-6(e)(2))
  [   ]  Definitive Proxy Statement
  [X]  Definitive Additional Materials
  [   ]  Soliciting Material Pursuant to § 240.14a-11(c) or § 240.14a-12

TENET HEALTHCARE CORPORATION


(Name of Registrant as Specified in Its Charter)

TENET SHAREHOLDER COMMITTEE, L.L.C.


(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):
  [X]  No fee required.
  [   ]  $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6a-6(i)(2) or Item 22(a)(2) of Schedule 14A.
  [   ]  Fee computed on table below per Exchange Act Rules 14a-6(i)(l) and 0-11.

      (1)  Title of each class of securities to which transaction applies:


      (2)  Aggregate number of securities to which transaction applies:


      (3)  Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):


      (4)  Proposed maximum aggregate value of transaction:


      (5)  Total fee paid:


      [   ]  Fee paid previously with preliminary materials.

      [   ]  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

      (1)  Amount previously paid:


      (2)  Form, Schedule or Registration Statement No.:


      (3)  Filing Party:


      (4)  Date Filed:



RELEASED TO SECURITY HOLDERS
ON SEPTEMBER 26, 2000


The Tenet Shareholder Committee, L.L.C.

     
Contact: Josh Pekarsky
Sarah Zitter Milstein
Kekst and Company
(212) 521-4800

TENET SHAREHOLDER COMMITTEE SHEDS LIGHT ON
TENET HEALTHCARE’S BROADLANE AFFAIR

NEW YORK, NY, September 26, 2000 – The Tenet Shareholder Committee, which is running a slate of four nominees for election to the Board of Directors of Tenet Healthcare Corporation (NYSE: THC) at its annual meeting on October 11th, today sent the following letter to the company’s shareholders.

Broadlane or Back Alley?

Dear Fellow Shareholder:

      Tenet’s management is benefiting from an investment, the Broadlane affair as we call it, that puts their personal interests ahead of yours. Their behavior is a reflection of the lack of accountability and deficient corporate governance standards at Tenet.

      In December 1999, Tenet Healthcare, led by CEO Jeffrey C. Barbakow, formed a private e-commerce subsidiary with corporate assets called Broadlane. In January 2000, Barbakow and other members of management each made personal investments in Broadlane at founders’ stock prices.

      In March 2000, Lehman Brothers analysts Adam Feinstein and Jeremy Raskin estimated that Broadlane could have a public market value of between $3 billion and $11 billion 1.

      At these valuations, Mr. Barbakow, who owns 2.3% of Broadlane, could walk away with a personal profit of between $67.8 million and $251.8 million dollars. According to Tenet’s recent definitive proxy statement, Barbakow’s personal investment already shows a neat personal profit of approximately  $3.6 million after just four months.

      It is the considered opinion of the Tenet Shareholder Committee that this investment stinks. It badly fails the most basic smell test and is a reflection of the near total lack of accountability at Tenet. It also raises some important questions for Mr. Barbakow and his cohorts:

  How are Tenet shareholders served by management’s personal investment in Broadlane?


1   “Medibuy.com Doubles Registered Buyers Via March 7 Premier Acquisition,” THE GRAY SHEET, Mar. 13, 2000, Vol. 26, Issue 11. Consent of author not obtained to use as proxy soliciting material.

 


  Why did the Company’s Board permit such obvious and significant conflicts of interest?
 
  Why do Tenet’s by-laws permit directors to vote on transactions or other matters in which they have a personal interest?
 
  Why is Jeff Barbakow using shareholders’ assets to set himself up to pocket up to a quarter billion dollars?

      To us, the Broadlane affair is a clear example of management’s priorities: self-enrichment over attention to Tenet’s core financial and operating deficiencies. It’s also clear evidence of a Board that is either in the dark when it comes to basic uses of shareholder assets, or in the dark ages when it comes to basic standards of good corporate governance and accountability.

      It’s time to shine a light on Tenet’s dark dealings, bring change and accountability to a stale Board of Directors, and remind management that its job isn’t to see how fat and happy it can be living off Tenet in sunny Santa Barbara. It is time for management to roll up its sleeves and create value for all shareholders by providing quality health care to its many patients.

      Please sign, date and return the enclosed striped GOLD proxy card today in the postage paid envelope provided. Please note that you can vote on all proposals on the enclosed striped GOLD proxy card.

  Sincerely,

  M. Lee Pearce, M.D.
Chairman
The Tenet Shareholder Committee

IMPORTANT:

If your shares are held in the name of your bank or broker, only they can vote your shares. Please
return the enclosed GOLD proxy card to your bank or broker in the envelope provided or contact
the person responsible for your account and give instructions to vote FOR the election of the
Committee’s nominees on Proposal 1.

IF YOU HAVE ANY QUESTIONS OR REQUIRE ANY ASSISTANCE IN VOTING YOUR
SHARES, PLEASE CONTACT: INNISFREE M&A INCORPORATED, TOLL-FREE AT

1-888-750-5834

E-MAIL: [email protected]

 



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission